Stock Alert: ASLAN Pharma Jumps 30% On Positive Data From Atopic Dermatitis Treatment Study

(RTTNews) - Shares of ASLAN Pharmaceuticals Limited (ASLN) jumped over 30% on Monday morning after the company announced positive interim data from a study of skin disease treatment.

ASLN is currently trading at $5.89, up $1.46 or 32.96%, on the Nasdaq.

ASLAN Pharma, a clinical-stage immunology focused biopharmaceutical company, announced positive interim data from study of ASLAN004 for the treatment of moderate to severe atopic dermatitis.

ASLAN004 was shown to be well tolerated across all doses and showed improvements compared to placebo in all efficacy endpoints, supporting its potential as a differentiated, novel treatment for AD.

Atopic dermatitis usually develops in early childhood and is more common in people who have a family history of the condition. The main symptom is a rash that typically appears on the arms and behind the knees, but can also appear anywhere.